Unknown

Dataset Information

0

Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition.


ABSTRACT: This study aimed to identify molecular determinants of sensitivity of non-small cell lung cancer (NSCLC) to anti-insulin-like growth factor receptor (IGF-IR) therapy.A total of 216 tumor samples were investigated, of which 165 consisted of retrospective analyses of banked tissue and an additional 51 were from patients enrolled in a phase II study of figitumumab, a monoclonal antibody against IGF-IR, in stage IIIb/IV NSCLC. Biomarkers assessed included IGF-IR, epidermal growth factor receptor, IGF-II, IGF-IIR, insulin receptor substrate 1 (IRS-1), IRS-2, vimentin, and E-cadherin. Subcellular localization of IRS-1 and phosphorylation levels of mitogen-activated protein kinase and Akt1 were also analyzed.IGF-IR was differentially expressed across histologic subtypes (P = 0.04), with highest levels observed in squamous cell tumors. Elevated IGF-IR expression was also observed in a small number of squamous cell tumors responding to chemotherapy combined with figitumumab (P = 0.008). Because no other biomarker/response interaction was observed using classical histologic subtyping, a molecular approach was undertaken to segment NSCLC into mechanism-based subpopulations. Principal component analysis and unsupervised Bayesian clustering identified three NSCLC subsets that resembled the steps of the epithelial to mesenchymal transition: E-cadherin high/IRS-1 low (epithelial-like), E-cadherin intermediate/IRS-1 high (transitional), and E-cadherin low/IRS-1 low (mesenchymal-like). Several markers of the IGF-IR pathway were overexpressed in the transitional subset. Furthermore, a higher response rate to the combination of chemotherapy and figitumumab was observed in transitional tumors (71%) compared with those in the mesenchymal-like subset (32%; P = 0.03). Only one epithelial-like tumor was identified in the phase II study, suggesting that advanced NSCLC has undergone significant dedifferentiation at diagnosis.NSCLC comprises molecular subsets with differential sensitivity to IGF-IR inhibition.

SUBMITTER: Gualberto A 

PROVIDER: S-EPMC2952544 | BioStudies | 2010-01-01

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | S-EPMC3388259 | BioStudies
2013-01-01 | S-EPMC3839884 | BioStudies
1000-01-01 | S-EPMC3759044 | BioStudies
2014-01-01 | S-EPMC4067944 | BioStudies
1000-01-01 | S-EPMC5360299 | BioStudies
2018-01-01 | S-EPMC5903866 | BioStudies
1000-01-01 | S-EPMC3262205 | BioStudies
2010-01-01 | S-EPMC2871434 | BioStudies
1998-01-01 | S-EPMC1219769 | BioStudies
2012-01-01 | S-EPMC3436179 | BioStudies